Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mastigen BB Jelly Tablets
- Development stage
- Unknown
- Lead developer
- Nippon Zoki Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mastigen BB Jelly Tablets is an oral, over-the-counter (OTC) combination of vitamins B2 (riboflavin butyrate), B6 (pyridoxine), B3 (nicotinamide), and C (ascorbic acid) developed and manufactured by Nippon Zoki Pharmaceutical. Formulated as a grapefruit-flavored chewable jelly tablet that can be taken without water, it is approved in Japan as a Class 3 OTC drug. The product is indicated for the treatment of rough skin, acne, stomatitis (canker sores), and physical fatigue by promoting collagen synthesis and maintaining healthy skin and mucous membranes.
- Brand names
- Mastigen BB Jelly Tablets
- Other names
- Masutigen BB Jelly TabletsマスチゲンBBゼリー錠
Beyond the preview
Go deeper on Mastigen BB Jelly Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mastigen BB Jelly Tablets.